Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer
Cancer Letters · 2026-06 · 648 · 218464
DOI: 10.1016/j.canlet.2026.218464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-06. Verfasst von Botai Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai, 200127, China; Westlake Un…. Hauptthemen laut MEDLINE: Cyclin B1, Pancreatic Neoplasms, CDC2 Protein Kinase, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiao Tong University, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Immunotherapies, especially immune checkpoint blockade, has achieved considerable success in multiple cancers; however, patients with "cold tumors", in particular pancreatic cancer, rarely respond, largely due to insufficient T cell activation and infiltration within the tumor microenvironment (TME). To understand the mechanisms whereby tumor cells regulate T cell activation, we conducted an in vivo CRISPR-Cas9 screen, and identified the CDK1/Cyclin B1 complex as a previously unrecognized tumor-intrinsic driver of immune evasion in pancreatic cancer. Genetic ablation or pharmacological inhibition of the CDK1/Cyclin B1 complex induced a T cell-inflamed TME, which synergized with PD-1 blockade to suppress tumor growth. Mechanistically, loss of Ccnb1 reduced phosphorylation of the retinoblastoma protein (Rb) at S249/T252 residues, and restored NF-κB activity, which elevated the production of granulocyte-macrophage colony-stimulating factor (GM-CSF), and promoted the recruitment and activation of conventional type 1 dendritic cells. Collectively, these findings uncover the CDK1/Cyclin B1 complex involved in tumor immune evasion and provide a compelling rationale for combining CDK1/Cyclin B1 inhibition with PD-1 blockade in the treatment of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai, 200127, China; Westlake University School of Medicine and New Cornerstone Science Laboratory, Ha…
- Institute for Immunology and School of Medicine, Tsinghua University, Beijing, 100084, China.
- Westlake University School of Medicine and New Cornerstone Science Laboratory, Hangzhou, Zhejiang, 310030, China; Institute for Immunology and School of Medicine, Tsinghua University, Beijing, 100084, China.
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
- Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai, 200127, China. Electronic address: zhangting@shsmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Shanghai Jiao Tong University
- China Postdoctoral Science Foundation
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Postdoctoral Program for Innovative Talents
Zitieren
APA
Li, B., Wei, P., Xie, B., Zhong, X., Wang, X., Lou, X., Zhang, T., & Dong, C. (2026). Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer. Cancer Letters, 648, 218464. https://doi.org/10.1016/j.canlet.2026.218464
Vancouver
Li B, Wei P, Xie B, Zhong X, Wang X, Lou X, et al. Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer. Cancer Letters. 2026;648:218464. doi:10.1016/j.canlet.2026.218464
BibTeX
@article{Li2026,
author = {Li, Botai and Wei, Peng and Xie, Bowen and Zhong, Xuan and Wang, Xiaoshuang and Lou, Xinyi and Zhang, Ting and Dong, Chen},
title = {Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer},
journal = {Cancer Letters},
year = {2026},
volume = {648},
pages = {218464},
doi = {10.1016/j.canlet.2026.218464}
}
EUVIMED